Comment on a published paper. The adverse cholinergic effects of the chemotherapeutic agent irinotecan (CPT-11) were unlikely to be mediated by the inhibition of acetylcholinesterase (AChE).
作者信息
Dodds H M, Rivory L P
出版信息
Br J Pharmacol. 2001 Sep;134(2):448-50. doi: 10.1038/sj.bjp.0704282.
Abstract
摘要
相似文献
1
Comment on a published paper. The adverse cholinergic effects of the chemotherapeutic agent irinotecan (CPT-11) were unlikely to be mediated by the inhibition of acetylcholinesterase (AChE).对一篇已发表论文的评论。化疗药物伊立替康（CPT - 11）的不良胆碱能效应不太可能由乙酰胆碱酯酶（AChE）抑制介导。
Br J Pharmacol. 2001 Sep;134(2):448-50. doi: 10.1038/sj.bjp.0704282.
2
The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variables.伊立替康及相关喜树碱对乙酰胆碱酯酶的抑制作用：关键结构特性与实验变量
Anticancer Drug Des. 2001 Aug-Oct;16(4-5):239-46.
3
Irinotecan (CPT-11): a brief overview.
Clin Exp Pharmacol Physiol. 1996 Oct-Nov;23(10-11):1000-4. doi: 10.1111/j.1440-1681.1996.tb01158.x.
4
Evaluation of HI-6 oxime: potential use in protection of human acetylcholinesterase inhibited by antineoplastic drug irinotecan and its cyto/genotoxicity in vitro.HI-6肟的评估：在保护受抗肿瘤药物伊立替康抑制的人乙酰胆碱酯酶方面的潜在用途及其体外细胞/遗传毒性
Acta Biochim Pol. 2007;54(3):583-93. Epub 2007 Aug 23.
5
Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11.抗癌前药CPT-11对乙酰胆碱酯酶的抑制作用。
Chem Biol Interact. 2005 Dec 15;157-158:247-52. doi: 10.1016/j.cbi.2005.10.033. Epub 2005 Oct 28.
6
Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: a preclinical study.乙酰胆碱酯酶阻断不能解释抗肿瘤药物伊立替康的不良心血管效应：一项临床前研究。
Toxicol Appl Pharmacol. 2001 Dec 1;177(2):149-56. doi: 10.1006/taap.2001.9293.
7
Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11).接受伊立替康（喜树碱-11）治疗患者中乙酰胆碱酯酶的抑制作用
Clin Pharmacol Ther. 2004 Nov;76(5):505-6; author reply 507-8. doi: 10.1016/j.clpt.2004.07.014.
8
The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action.抗癌前药7-乙基-10-[4-(1-哌啶基)-1-哌啶基]-羰氧基喜树碱（CPT-11）与加州电鳐乙酰胆碱酯酶复合物的晶体结构为其胆碱能作用提供了分子解释。
Mol Pharmacol. 2005 Jun;67(6):1874-81. doi: 10.1124/mol.104.009944. Epub 2005 Mar 16.
9
The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11).伊立替康（CPT-11）抑制乙酰胆碱酯酶的机制。
Mol Pharmacol. 1999 Dec;56(6):1346-53. doi: 10.1124/mol.56.6.1346.
10
Gastrointestinal toxicity or irinotecan.胃肠道毒性或伊立替康。
Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):72-8.
本文引用的文献
1
Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan.一种解释抗癌药物伊立替康不良胆碱能效应的新机制的表征。
Br J Pharmacol. 2001 Jan;132(1):73-84. doi: 10.1038/sj.bjp.0703766.
2
The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11).伊立替康（CPT-11）抑制乙酰胆碱酯酶的机制。
Mol Pharmacol. 1999 Dec;56(6):1346-53. doi: 10.1124/mol.56.6.1346.
3
The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase.
Cancer Res. 1999 Apr 1;59(7):1458-63.
4
Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.从患者血浆中分离出的伊立替康（CPT-11）主要血浆代谢物的鉴定及其性质
Cancer Res. 1996 Aug 15;56(16):3689-94.
5
Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats.喜树碱衍生物对犬乙酰胆碱酯酶的抑制活性及其对大鼠乙酰胆碱受体的结合活性。
J Pharm Pharmacol. 1993 May;45(5):444-8. doi: 10.1111/j.2042-7158.1993.tb05573.x.
6
7
Ellman's reagent: 5,5'-dithiobis(2-nitrobenzoic acid)--a reexamination.埃尔曼试剂：5,5'-二硫代双（2-硝基苯甲酸）——重新审视
Anal Biochem. 1979 Apr 1;94(1):75-81. doi: 10.1016/0003-2697(79)90792-9.
Zotero 插件